FDA Brief

Warning letters Drugs

FDA warning letter to

Abraxis Bioscience LLC

High riskIssued Oct 31, 2022Posted Nov 8, 2022Center for Drug Evaluation and Research | CDER

FDA warned Abraxis Bioscience about repeated contamination in media fills for sterile Abraxane at its Phoenix plant.

What happened

FDA inspected the Phoenix facility from March 28 to April 6, 2022. It found multiple media fill failures from April to October 2021 on the aseptic filling line for Abraxane; media fills simulate sterile filling and showed contaminated units. FDA said the investigations and corrective actions were inadequate, and the company released potentially affected batches after one successful November 2021 media fill.

What FDA found

  1. The company failed to thoroughly investigate unexplained discrepancies or batch failures, including media fill failures.

    21 CFR 211.192
  2. The company failed to effectively carry out corrective and preventive actions (CAPA) and bring its aseptic filling line back into control after repeated media fill failures.

    21 CFR parts 210 and 211
  3. The media fill investigations did not adequately determine root causes or the full impact of serious non-sterility risks.

  4. The company released batches potentially affected by the media fill failures after one successful November 2021 media fill.

  5. The company's response was inadequate because contaminated media fills recurred and it lacked a comprehensive contamination risk assessment and holistic remediation.

  6. The company did not adequately evaluate the suitability and robustness of disposable aseptic equipment and sampling systems, or disinfection of the restricted access barrier system (RABS) and cleanrooms.

What FDA wants

FDA asks Abraxis to provide a comprehensive contamination risk assessment, detailed remediation and CAPA plans, independent reviews of investigations and sterilization, a list of Abraxane complaints since 2019, and an updated patient-risk assessment for certain batches, and to respond in writing within 15 working days.

Who should pay attention

  • makers of sterile injectables
  • companies using similar disposable aseptic filling systems
  • clinicians and distributors handling Abraxane

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk